The National Institute for Health and Care Excellence (Nice) said it is "extremely disappointed" it will be unable to ...

AZ and Daiichi Sankyo have said that NICE's decision on Enhertu exposes how new methods and processes the agency uses to ...

Nice said it was ‘extremely disappointed’ it will be unable to recommend trastuzumab deruxtecan, sold under the brand name ...

Talks with AZ and Daiichi to negotiate a fair price for Enhertu for treatment of advanced HER2-low breast cancer in the U.K.

In the talks both ourselves and NHS England continued to offer as much flexibility as possible, but despite the intervention of Secretary of State for Health Wes Streeting, the companies did not put ...

It comes after Health Secretary Wes Streeting met with the charity Breast Cancer Now to discuss the issue around Enhertu. In a post on X, formerly Twitter, from October 24 he wrote: "An improved offer ...

A woman whose cancer has spread to her bones, back, pelvis and neck but has been denied a life-extending drug because she lives in Wales says she "wants a chance to live". Rachel Davies, 40, from ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...

The European Commission has approved Daiichi Sankyo and AstraZeneca's Enhertu as the first targeted therapy for HER2-low breast cancer, unlocking a large population of patients who could be ...

Rachel Davies, 40, from Swansea, was diagnosed with secondary breast cancer in 2021. The drug, called Enhertu, can give patients with a specific type of incurable breast cancer an extra six months ...

Trodelvy shows consistent efficacy in metastatic triple-negative breast cancer with a 27.8% ORR and 4.8 months PFS. Enhertu demonstrates promising results in HER2-low patients post-Trodelvy, achieving ...